Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-25
2009-10-13
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000
Reexamination Certificate
active
07601701
ABSTRACT:
The invention provides methods for treating or suppressing tobacco or nicotine usage or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
REFERENCES:
patent: 4027017 (1977-05-01), Hata et al.
patent: 4048316 (1977-09-01), Penn
patent: 4115576 (1978-09-01), Penn
patent: 4704361 (1987-11-01), Miccoli et al.
patent: 4999382 (1991-03-01), Wurtman
patent: 5179126 (1993-01-01), Wurtman
patent: 5278176 (1994-01-01), Lin
patent: 5409946 (1995-04-01), Garvey et al.
patent: 5472958 (1995-12-01), Gunn, Jr. et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5919789 (1999-07-01), Dyke et al.
patent: 5958896 (1999-09-01), Renshaw et al.
patent: 5977174 (1999-11-01), Bradley et al.
patent: 6103703 (2000-08-01), Renshaw et al.
patent: 6153653 (2000-11-01), Shashoua
patent: 6277855 (2001-08-01), Yerxa
patent: 2002/0019364 (2002-02-01), Renshaw
patent: 2002/0182196 (2002-12-01), McCleary
patent: 2003/0114415 (2003-06-01), Wurtman et al.
patent: 2003/0220291 (2003-11-01), Renshaw
patent: 2004/0176316 (2004-09-01), Renshaw et al.
patent: 3400276 (1985-07-01), None
patent: 0 188647 (1986-07-01), None
patent: 0218190 (1987-04-01), None
patent: 0218190 (1989-11-01), None
patent: 63-202854 (1988-08-01), None
patent: 08183737 (1996-07-01), None
patent: WO 99/26620 (1999-06-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 01/72288 (2001-10-01), None
Agnoli, et al., “Efficacy of CDP choline in Chronic Vascular Diseases (CCVD),”Novel Biochemical, Pharmacological and Clinical Aspects of CytidinediphosphocholineElsevier (1985) 305-315.
Babb, et al., “Differential Effect of CDP-choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy,”Psychopharmacology(1996) 127:88-94.
Boudouresques, et al., “Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-choline,”International Symposium: Brain Suffering and Precursors of Phospholipidspp. 1-13 (1980).
Brown et al., “CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology,”Am. J. Roentgenol.(1992) 159:137-147.
Centrone et al., “Use of Citicoline in High Dosages in Acute Cerebrovascular Disease,”Minerva Med.(1986) 77:371-373 (English Abstract).
Chang et al., “Neurochemical Alterations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study,”Biol. Psychiatry(1997) 42:1105-1114.
Christensen et al., “Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A31P MR Spectroscopy Study,”Magn. Reson. Med.(1996) 35:658-663.
Citicoline Sodium (CDP-Choline),Investigator's Brochure, Revised: Apr. 1994 by Interneuron Pharmaceuticals, Inc.
Cohen et al., “Decreased Brain Choline Uptake in Older Adults,”JAMA(1995) 274:902-907.
English et al., “Elevated Frontal Lobe Cytosolic Choline Levels in Minimal or Mild AIDS Dementia Complex Patients: A Proton Magnetic Resonance Spectroscopy Study,”Biol. Psychiatry(1997) 41:500-502.
Gallai et al., “Study of the P300 and Cerebral Maps in Subjects with Multi-Infarct Dementia Treated with Cytidine,”Psychopharmacology(1991) 103:1-5.
Galletti et al., “Biochemical Rationale for the Use of CDP-choline in Traumatic Brain Injury: Pharmacokinetics of the Orally Administered Drug,”J. Neurol. Sci.(1991) 103:S19-S25.
Hoff et al., “Effects of Crack Cocaine on Neurocognitive Function,”Psychiatry Res.(1996) 60:167-176.
Jacobs et al., “Cocaine Abuse: Neurovascular Complications,”Radiology(1989)170:223-227.
Kaufman et al., “Cocaine-Induced Cerebral Vasoconstriction Detected in Humans with Magnetic Resonance Angiography,”JAMA(1998) 279:376-380.
Kreek “Opiate and Cocaine Addictions: Challenge for Pharmacotherapies,” i Pharmacol. Biochem. Behav. (1997) 57:551-569.
Levin et al., “Improved Regional Cerebral Blood Flow in Chronic Cocaine Polydrug Users Treated with Buprenorphine,”J. Nucl. Med.(1995) 36:1211-1215.
London et al., “Cerebral Glucose Utilization in Human Heroin Addicts: Case Reports from a Positron Emission Tomographic Study,” Res. Commun. Subst. Abuse (1989) 10:141-144.
Lukacsko et al., “Modulation of the Vasoconstrictor Response to Adrenergic Stimulation by Nucleosides and Nucleotides,”J. Pharmacol. Exp. Ther.(1982) 222:344-349.
Lukas et al., “Effects of Short-term Citicoline Treatment on Acute Cocaine Intoxication and Cardiovascular Effects,”Psychopharmacology(2001) 157:163-7.
Maas et al., “Functional Magnetic Resonance Imaging of Human Brain Activation During Cue-induced Cocaine Craving,”Am. J. Psychiatry(1998) 155:124-126.
Malec et al., “Influence of Adenosinergic Drugs on Ethanol Withdrawal Syndrome in Rats,”Pol. J. Pharmacol.(1996) 48:583-588.
McCance, “Overview of Potential Treatment Medications for Cocaine Dependence,”NIDA Res. Monogr.,(1997) 175:36-72.
Moglia et al., “Citicoline in Patients with Chronic Cerebrovascular Diseases (CCVD): Quantitative EEG Study,” Curr.Ther. Res.(1984) 36:309-313.
Monticone et al., “On the Therapeutic Use of Nucleosides, Cytidine and Uridine, in some Neurological Diseases,”Minerva Med.(1966) 57:4348-52.
O'Rourke et al., “Effect of Chronic Cocaine Exposure on Carotid Artery Reactivity in Neonatal Rabbits,”Life Sci.(1996) 59:119-130.
Page, et al., “Developmental Disorder Associated with Increased Cellular Nucleotidase Activity,”Proc. Natl. Acad. Sci. USA(1997) 94:11601-11606.
Peterson et al., “Neurovascular Complications of Cocaine Abuse,”J. Neuropsychiatry Clin. Neurosci.,(1991) 3:143-149.
Renshaw et al., “Short-term Treatment with Citicoline (CDP-choline) Attenuates Some Measures of Craving in Cocaine-Dependent Subjects: A Preliminary Report,”Psychopharmacology(1999) 142:132-8.
Saligaut et al., “Circling Behaviour in Rats with Unilateral Lesions of the Nigrostriatum Induced by 6-Hydroxydopamine: Changes Induced by Oral Administration of Cytidine-5′- Diphosphocholine,”Neuropharmacology(1987) 26:1315-1319.
Salvadorini et al., “Clinical Evaluation of CDP-choline (Nicholin®): Efficacy as Antidepressant Treatment,”Curr. Ther. Res.(1975) 18:513-520.
Secades et al., “CDP-choline: Pharmacological and Clinical Review,”Meth. Find. Exp. Clin. Pharmacol.(1995) 17(Suppl. B):1-54.
Self, et al., “Opposite Modulation of Cocaine-seeking Behavior by D1- and D2-like Dopamine Receptor Agonists,”Science(1996) 271:1586-1589.
Shekim et al., “S-Adenosyl-L-Methionine (SAM) in Adults with ADHD, RS: Preliminary Results from an Open Trial,”Psychopharmacol. Bull.(1990) 26:249-253.
Sholar et al., “Concurrent Pharmacokinetic Analysis of Plasma Cocaine and Adrenocorticotropic Hormone in Men,”J. Clin. Endocrinol. Metab.(1998) 83:966-968.
Tazaki et al., “Treatment of Acute Cerebral Infarction with a Choline Precursor in a Multicenter Double-Blind Placebo-Controlled Study,”Stroke(1988) 19:211-216.
Teoh et al., “Acute Interactions of Buprenorphine with Intravenous Cocaine and Morphine: An Investigational New Drug Phase I Safety Evaluation,”J. Clin. Psychopharmacol.(1993) 13:87-99.
Tornos et al., “Effect of Oral CDP-Choline on Experimental Withdrawal Syndrome,”Arzneim.-Forsch./Drug Res.(1983) 33:1018-1021.
Warner et al., “Pharmacotherapy for Opioid and Cocaine Abuse,”Med. Clin. North Am.(1997) 81:909-925.
Weiss, “Metabolism and Actions of CDP-Choline as an Endogenous Compound and Administered Exogenously as Citicoline,”Life Sci.(1995) 56:637-660.
Wurtman et al., “Effect of Oral CDP-choli
Clark & Elbing LLP
Lewis Patrick T
The McLean Hospital Corporation
LandOfFree
Compounds for the treatment of tobacco dependence and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of tobacco dependence and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of tobacco dependence and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085057